Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Moderna’s COVID-19 vaccine maintains antibodies to six months, study shows

New data published on the durability of the Moderna COVID-19 vaccine in generating neutralising antibodies against variants of concern has shown that the majority of individuals vaccinated maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose.

This study used a variety of assays and showed that antibodies were generated against Alpha, Beta, Gamma, Delta, Epsilon and Iota variants. While some waning in antibody levels was observed over time, the majority of participants had detectable neutralising antibody titers at six months after the completion of the primary series.

A trend towards lower antibody levels against SARS-CoV-2 spike variants was observed in the oldest individuals at Day 209.

“Along with our partners, we are committed to generating data on the Moderna COVID-19 vaccine and sharing this as available,” said Stéphane Bancel, chief executive officer of Moderna.

“[This] data support[s] the durable efficacy of 93% seen with the Moderna COVID-19 vaccine through six months. We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” he added.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025